AbbVie Inc.

Good morning, and thank you for standing by. Welcome to the AbbVie first quarter 2023 earnings conference call. All participants will be able to listen only until the question and answer portion of this call. You may ask a question by pressing star 1 on your phone. I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.

Good morning, and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer, Rob Michael, Vice Chairman and President, Jeff Stewart, Executive Vice President and Chief Commercial Officer. Scott Rentz, Executive Vice President and Chief Financial Officer. Carrie Strom, Senior Vice President and President Allergan Aesthetics. And Tom Hudson, Senior Vice President R&D and Chief Scientific Officer. Joining us for the Q&A portion of the call is Rupal Thakkar, Senior Vice President Development and Regulatory Affairs and Chief Medical Officer. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. Abbey cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. Abbey undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand Abbey's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rick.

Thank you, Liz. Good morning, everyone, and thank you for joining us today. I'm extremely pleased with our start to 2023, with first quarter total revenues and adjusted earnings per share both exceeding our expectations. This performance was driven by Double-digit sales growth from several key products, including Skyrizzy, Rynvoke, Benklexta, and Valar. Positive momentum from our aesthetics business, with strong results internationally and stabilizing consumer trends in the U.S. An in-line performance from U.S. Humira, where biosimilar erosion is tracking as expected, with much of the impact driven by price. Since our inception, We have successfully created a well-diversified portfolio with multiple growth platforms in highly attractive markets, including immunology, hematological oncology, neuroscience, and aesthetics. Our commercial execution, including the launch of new products and expanded indications, has been outstanding, especially across SkyRise and Renvoke, and recently with Valar and MDD. Each of these assets are expected to contribute significant revenue growth over the decade. The breadth and the depth of our R&D pipeline also supports our long-term growth outlook, and we anticipate numerous important pipeline milestones over the next two years. In summary, we are one quarter into the U.S. biosimilar event for Jumeirah and are managing the erosion well. Most importantly, our growth platform is demonstrating strong performance, exceeding our expectations. We are executing well across all aspects of our business and see numerous opportunities for our diverse portfolio to drive long-term growth. With that, I'll turn the call over to Rob for additional comments on our business performance.